SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.0685-2.1%Nov 4 3:39 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Howard Williams6/10/2014 9:10:03 AM
1 Recommendation

Recommended By
Mark Buczynski

   of 13111
 
Provectus News PV-10 produced complete response in 50% of advanced melanoma patients
Tuesday June 10, 2014
An article appearing in Medical News Today entitled "PV-10 produced complete response in 50% of advanced melanoma patients" reports on Phase 2 PV-10 data recently presented at the 50th American Society of Clinical Oncology meeting (ASCO)). The analysis presented at ASCO shows that half of patients with locally advanced cutaneous melanoma who had all their lesions injected with PV-10 achieved a complete response.

The article is available at http://www.medicalnewstoday.com/articles/277977.php on the Medical News Today website.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News